{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T05:34:07Z","timestamp":1762234447170,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Trastuzumab deruxtecan (T-DXd) has demonstrated efficacy in HER2-positive and HER2-low breast cancer. Its main safety concern is interstitial lung disease, while clinically relevant hepatotoxicity is rarely reported. In our case report we describe a 49-year-old woman with HER2-positive advanced breast cancer that developed persistent grade 3 transaminase elevations after 2 cycles of T-DXd, refractory to corticosteroid treatment and requiring treatment discontinuation. This case underlines the unpredictable and idiosyncratic nature of T-DXd associated hepatotoxicity and the importance of liver function monitoring. Clinicians should consider DILI in patients with unexplained liver enzyme elevations during therapy. Further studies are needed to clarify mechanisms and risk factors.<\/jats:p>","DOI":"10.3390\/curroncol32110606","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:21:46Z","timestamp":1762194106000},"page":"606","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Idiosyncratic Drug-Induced Liver Injury and Trastuzumab Deruxtecan in Breast Cancer: A Case Report"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6765","authenticated-orcid":false,"given":"Camilla","family":"Lisanti","sequence":"first","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4362-4889","authenticated-orcid":false,"given":"Serena","family":"Della Rossa","sequence":"additional","affiliation":[{"name":"Department of Medicine (DMED), University of Udine, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Zottarelli","sequence":"additional","affiliation":[{"name":"Department of Medicine (DMED), University of Udine, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Vida","sequence":"additional","affiliation":[{"name":"Department of Medicine (DMED), University of Udine, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bolzonello","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-1685","authenticated-orcid":false,"given":"Lucia","family":"Da Ros","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Zdjelar","sequence":"additional","affiliation":[{"name":"Department of Oncologic Radiation Therapy and Diagnostic Imaging, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7517-7490","authenticated-orcid":false,"given":"Erika","family":"Cecchin","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Perin","sequence":"additional","affiliation":[{"name":"Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[{"name":"Department of Medicine (DMED), University of Udine, 33100 Udine, Italy"},{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s11523-024-01079-4","article-title":"Trastuzumab-Deruxtecan: Redefining HER2 as a Tumor Agnostic Biomarker","volume":"19","author":"Zouein","year":"2024","journal-title":"Target. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hegg","year":"2023","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Park","year":"2023","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"LBA1008","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1008","article-title":"Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2\u2013positive (HER2+) advanced\/metastatic breast cancer (a\/mBC): Interim results from DESTINY-Breast09","volume":"43","author":"Tolaney","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"73","article-title":"Drug-induced Liver Injury","volume":"6","author":"David","year":"2010","journal-title":"US Gastroenterol. Hepatol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3121\/cmr.2008.825","article-title":"Breast Cancer Subtypes Based on ER\/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival","volume":"7","author":"Onitilo","year":"2009","journal-title":"Clin. Med. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Kim","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/14740338.2023.2277801","article-title":"A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system","volume":"23","author":"Sun","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1021\/acs.jmedchem.0c00524","article-title":"Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance\/Mitigation Strategies","volume":"63","author":"Norman","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1053\/j.gastro.2013.12.032","article-title":"Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives","volume":"146","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.102.041624","article-title":"Inflammation and Drug Idiosyncrasy\u2014Is There a Connection?","volume":"307","author":"Roth","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.15171\/apb.2016.076","article-title":"Concurrent Inflammation Augments Antimalarial Drugs-Induced Liver Injury in Rats","volume":"6","author":"Niknahad","year":"2016","journal-title":"Adv. Pharm. Bull."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejim.2021.10.035","article-title":"Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management","volume":"97","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1093\/annonc\/mdx158","article-title":"Drug-induced liver injury in Oncology","volume":"28","author":"Ricart","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Danan, G., and Teschke, R. (2015). RUCAM in Drug and Herb Induced Liver Injury: The Update. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010014"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case Definition and Phenotype Standardization in Drug-Induced Liver Injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/apt.17762","article-title":"Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum","volume":"59","author":"Palmer","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/apt.18271","article-title":"Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients","volume":"60","author":"Fettiplace","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2021.12.043","article-title":"Value of liver biopsy in the diagnosis of drug-induced liver injury","volume":"76","author":"Ahmad","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e16097","DOI":"10.1111\/liv.16097","article-title":"Role of liver biopsy in the management of idiosyncratic DILI","volume":"45","author":"Kleiner","year":"2025","journal-title":"Liver Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports","volume":"63","author":"Hoofnagle","year":"2016","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/1752-1947-8-417","article-title":"Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: A case report","volume":"8","author":"Ishizuna","year":"2014","journal-title":"J. Med. Case Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/annonc\/mdm515","article-title":"Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer","volume":"18","author":"Carrera","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000346844","article-title":"Trastuzumab-Induced Hepatotoxicity: A Case Report","volume":"8","author":"Vucicevic","year":"2013","journal-title":"Breast Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1345\/aph.1L217","article-title":"Trastuzumab-Induced Hepatotoxicity","volume":"42","author":"Srinivasan","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40264-021-01051-5","article-title":"Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials","volume":"44","author":"Seekins","year":"2021","journal-title":"Drug Saf."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rnsson, E.S., Vucic, V., Stirnimann, G., and Robles-D\u00edaz, M. (2022). Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.820724"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/11\/606\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T05:32:26Z","timestamp":1762234346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/11\/606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["curroncol32110606"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32110606","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2025,10,31]]}}}